Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: A report from the Eastern Cooperative Oncology Group

Martin S. Tallman, Haesook T. Kim, Elisabeth M. Paietta, John M. Bennett, Gordon Dewald, Peter A. Cassileth, Peter H. Wiernik, Jacob M. Rowe

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Purpose: Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML. and to identify differences in M5a and M5b. Patients and Methods: We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results: The complete remission rate was 62% for all patients with M5; 52% for patients with M5a and 65% for patients with M5b (P = .3), and 60% for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 vnon-M5). The 3-year disease-free survival was 26% for all M5 patients; 18% for M5a and 28% for M5b (P = .31), and 33% for non-M5 patients (P = .13 for M5 vnon-M5). The 3-year overall survival was 31% for all M5 patients; 33% for M5a and 30% for M5b (P = .65), and 30% for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53%) compared to M5b (77%) to a significant degree (P = .02). Conclusion: AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.

Original languageEnglish (US)
Pages (from-to)1276-1286
Number of pages11
JournalJournal of Clinical Oncology
Volume22
Issue number7
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Leukemia, Monocytic, Acute
Acute Myeloid Leukemia
Disease-Free Survival
Clinical Trials
Survival
Karyotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia : A report from the Eastern Cooperative Oncology Group. / Tallman, Martin S.; Kim, Haesook T.; Paietta, Elisabeth M.; Bennett, John M.; Dewald, Gordon; Cassileth, Peter A.; Wiernik, Peter H.; Rowe, Jacob M.

In: Journal of Clinical Oncology, Vol. 22, No. 7, 2004, p. 1276-1286.

Research output: Contribution to journalArticle

Tallman, Martin S. ; Kim, Haesook T. ; Paietta, Elisabeth M. ; Bennett, John M. ; Dewald, Gordon ; Cassileth, Peter A. ; Wiernik, Peter H. ; Rowe, Jacob M. / Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia : A report from the Eastern Cooperative Oncology Group. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 7. pp. 1276-1286.
@article{46efdabcbb1846d5b237f0a7901ac072,
title = "Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: A report from the Eastern Cooperative Oncology Group",
abstract = "Purpose: Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML. and to identify differences in M5a and M5b. Patients and Methods: We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results: The complete remission rate was 62{\%} for all patients with M5; 52{\%} for patients with M5a and 65{\%} for patients with M5b (P = .3), and 60{\%} for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 vnon-M5). The 3-year disease-free survival was 26{\%} for all M5 patients; 18{\%} for M5a and 28{\%} for M5b (P = .31), and 33{\%} for non-M5 patients (P = .13 for M5 vnon-M5). The 3-year overall survival was 31{\%} for all M5 patients; 33{\%} for M5a and 30{\%} for M5b (P = .65), and 30{\%} for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53{\%}) compared to M5b (77{\%}) to a significant degree (P = .02). Conclusion: AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.",
author = "Tallman, {Martin S.} and Kim, {Haesook T.} and Paietta, {Elisabeth M.} and Bennett, {John M.} and Gordon Dewald and Cassileth, {Peter A.} and Wiernik, {Peter H.} and Rowe, {Jacob M.}",
year = "2004",
doi = "10.1200/JCO.2004.08.060",
language = "English (US)",
volume = "22",
pages = "1276--1286",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia

T2 - A report from the Eastern Cooperative Oncology Group

AU - Tallman, Martin S.

AU - Kim, Haesook T.

AU - Paietta, Elisabeth M.

AU - Bennett, John M.

AU - Dewald, Gordon

AU - Cassileth, Peter A.

AU - Wiernik, Peter H.

AU - Rowe, Jacob M.

PY - 2004

Y1 - 2004

N2 - Purpose: Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML. and to identify differences in M5a and M5b. Patients and Methods: We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results: The complete remission rate was 62% for all patients with M5; 52% for patients with M5a and 65% for patients with M5b (P = .3), and 60% for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 vnon-M5). The 3-year disease-free survival was 26% for all M5 patients; 18% for M5a and 28% for M5b (P = .31), and 33% for non-M5 patients (P = .13 for M5 vnon-M5). The 3-year overall survival was 31% for all M5 patients; 33% for M5a and 30% for M5b (P = .65), and 30% for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53%) compared to M5b (77%) to a significant degree (P = .02). Conclusion: AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.

AB - Purpose: Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML. and to identify differences in M5a and M5b. Patients and Methods: We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results: The complete remission rate was 62% for all patients with M5; 52% for patients with M5a and 65% for patients with M5b (P = .3), and 60% for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 vnon-M5). The 3-year disease-free survival was 26% for all M5 patients; 18% for M5a and 28% for M5b (P = .31), and 33% for non-M5 patients (P = .13 for M5 vnon-M5). The 3-year overall survival was 31% for all M5 patients; 33% for M5a and 30% for M5b (P = .65), and 30% for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53%) compared to M5b (77%) to a significant degree (P = .02). Conclusion: AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.

UR - http://www.scopus.com/inward/record.url?scp=2142699469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142699469&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.08.060

DO - 10.1200/JCO.2004.08.060

M3 - Article

C2 - 14970186

AN - SCOPUS:2142699469

VL - 22

SP - 1276

EP - 1286

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -